FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W96749658> ?p ?o ?g. }

• W96749658 endingPage "412" @default.
• W96749658 startingPage "397" @default.
• W96749658 abstract "Leukopenia or pancytopenia as a result of bone marrow dysfunction are manifestations of various diseases or complications of therapeutic regimens. The spectrum of diseases associated with leukopenia is wide and includes congenital as well as acquired neutropenias secondary to conditions such as myelodysplastic syndromes, AIDS, malignant tumors with or without chemotherapy-enhanced neutropenia, bone marrow transplantation or therapeutic or accidental radiation. The morbidity and mortality of infectious diseases is greatly enhanced during neutropenic phases. Over the last few years attempts have been made to shorten the duration and lessen the severity of neutropenia in patients with the above conditions by administration of Granulocyte Macrophage Colony Stimulating Factor (G-CSF). Both cytokines were successfully tested in phase I and II trials. Treatment with GM-CSF or G-CSF results in a dose-dependent increase of the neutrophil count. GM-CSF also increases the number of eosinophils and monocytes in peripheral blood. The effect of both cytokines on the neutrophil count is transient as long as the underlying disease persists. This prompted the institution of maintenance therapy, which has been successfully used with either cytokine. Long-term treatment is usually well tolerated and results in a reduction in the frequency of infections as well as in the duration of antibiotic treatments. Side effects of GM-CSF or G-CSF are usually mild and include fever, myalgia, bone pain, and erythema. A number of patients developed dyspnea, hypotension, sweating, flushing and erythema after the first dose of GM-CSF in each treatment cycle. This first-dose reaction occurs more frequently after intravenous than reactions were reported with G-CSF. Some patients with myelodysplastic syndrome progressed to acute myeloic leukemia during or after treatment with GM-CSF or G-CSF. Most of these patients presented with an increased fraction of blasts in the bone marrow, which preceded the treatment with the colony stimulating factors. Since GM-CSF and possibly G-CSF may increase the risk of developing acute leukemia in patients with myelodysplastic syndrome, it appears prudent to limit the use of these cytokines in patients with this disease. The subcutaneous route of administration appears to be preferable to intravenous administration, since the incidence and severity of side effects are reduced. While many questions concerning dosage, long-term therapy and combination therapy still remain unanswered, the information presented in this review concerning the clinical use of these cytokines warrants an optimistic outlook." @default.
• W96749658 created "2016-06-24" @default.
• W96749658 creator A5005447367 @default.
• W96749658 creator A5016897336 @default.
• W96749658 date "1991-03-23" @default.
• W96749658 modified "2023-09-23" @default.
• W96749658 title "[GM-CSF and G-CSF: cytokines in clinical application]." @default.
• W96749658 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/1709294" @default.
• W96749658 hasPublicationYear "1991" @default.
• W96749658 type Work @default.
• W96749658 sameAs 96749658 @default.
• W96749658 citedByCount "5" @default.
• W96749658 countsByYear W967496582013 @default.
• W96749658 countsByYear W967496582023 @default.
• W96749658 crossrefType "journal-article" @default.
• W96749658 hasAuthorship W96749658A5005447367 @default.
• W96749658 hasAuthorship W96749658A5016897336 @default.
• W96749658 hasConcept C126322002 @default.
• W96749658 hasConcept C203014093 @default.
• W96749658 hasConcept C2776139714 @default.
• W96749658 hasConcept C2776694085 @default.
• W96749658 hasConcept C2777063308 @default.
• W96749658 hasConcept C2778594517 @default.
• W96749658 hasConcept C2778616394 @default.
• W96749658 hasConcept C2779382419 @default.
• W96749658 hasConcept C2780007613 @default.
• W96749658 hasConcept C2780873365 @default.
• W96749658 hasConcept C71924100 @default.
• W96749658 hasConcept C74133956 @default.
• W96749658 hasConcept C90924648 @default.
• W96749658 hasConceptScore W96749658C126322002 @default.
• W96749658 hasConceptScore W96749658C203014093 @default.
• W96749658 hasConceptScore W96749658C2776139714 @default.
• W96749658 hasConceptScore W96749658C2776694085 @default.
• W96749658 hasConceptScore W96749658C2777063308 @default.
• W96749658 hasConceptScore W96749658C2778594517 @default.
• W96749658 hasConceptScore W96749658C2778616394 @default.
• W96749658 hasConceptScore W96749658C2779382419 @default.
• W96749658 hasConceptScore W96749658C2780007613 @default.
• W96749658 hasConceptScore W96749658C2780873365 @default.
• W96749658 hasConceptScore W96749658C71924100 @default.
• W96749658 hasConceptScore W96749658C74133956 @default.
• W96749658 hasConceptScore W96749658C90924648 @default.
• W96749658 hasIssue "12" @default.
• W96749658 hasLocation W967496581 @default.
• W96749658 hasOpenAccess W96749658 @default.
• W96749658 hasPrimaryLocation W967496581 @default.
• W96749658 hasRelatedWork W1999927079 @default.
• W96749658 hasRelatedWork W2022344519 @default.
• W96749658 hasRelatedWork W2130245854 @default.
• W96749658 hasRelatedWork W2355003292 @default.
• W96749658 hasRelatedWork W2380496346 @default.
• W96749658 hasRelatedWork W2399260915 @default.
• W96749658 hasRelatedWork W2790898433 @default.
• W96749658 hasRelatedWork W78271696 @default.
• W96749658 hasRelatedWork W96749658 @default.
• W96749658 hasRelatedWork W2909144384 @default.
• W96749658 hasVolume "121" @default.
• W96749658 isParatext "false" @default.
• W96749658 isRetracted "false" @default.
• W96749658 magId "96749658" @default.
• W96749658 workType "article" @default.